Walgreens Boots Alliance, Inc.

NasdaqGS:WBA 株式レポート

時価総額：US$10.3b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Walgreens Boots Alliance マネジメント

マネジメント 基準チェック /34

Walgreens Boots Allianceの CEO はTim Wentworthで、 Oct2023年に任命され、 の在任期間は 1.83年です。 の年間総報酬は$ 13.50Mで、 9.6%給与と90.4%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.015%を直接所有しており、その価値は$ 1.59M 。経営陣と取締役会の平均在任期間はそれぞれ2.1年と3.9年です。

主要情報

Tim Wentworth

最高経営責任者

US$13.5m

報酬総額

CEO給与比率9.56%
CEO在任期間1.8yrs
CEOの所有権0.02%
経営陣の平均在職期間2.1yrs
取締役会の平均在任期間3.9yrs

経営陣の近況

Recent updates

Seeking Alpha • Jul 29

Walgreens Boots Alliance: Merger Arbitrage Opportunity

Summary Walgreens Boots Alliance is going private at $11.45/share plus up to $3 via a CVR, offering a potential $14.45 payout. The market is undervaluing the deal, ignoring both the turnaround momentum and the upside from the CVR, creating a merger arbitrage opportunity. Risks include regulatory approval and deal financing, but shareholder approval is secured and the buyer is known, making this a clean, short-term trade. WBA is a buy for merger arbitrage, capture the spread before the deal closes for a potential 25% return. Read the full article on Seeking Alpha
Seeking Alpha • Apr 15

Walgreens: Acquisition Is The Best-Case Scenario For The Company

Summary Walgreens Boots Alliance faces significant challenges, including rising inflation, heavy competition, and decreasing profitability, making it a Hold if the acquisition by Sycamore goes through. The company's financial health is concerning, with declining net income, negative free cash flow, and high debt levels, increasing the vulnerability to financial downturns. WBA's lack of its own Pharmacy Benefit Manager (PBM) puts it at a disadvantage compared to CVS, which owns Caremark and can better manage drug prices. If the acquisition proceeds, there's a potential 34.92% upside for shareholders; without it, WBA is overvalued, and I would rate it a Strong Sell. Read the full article on Seeking Alpha
Seeking Alpha • Mar 07

What To Do After Sycamore Partners Agrees To Buy Walgreens

Summary Sycamore Partners will acquire Walgreens Boots Alliance, Inc. for up to $23.7 billion, with WBA stock rising 7.3% to $11.38 post-announcement. Long-term investors may vote against the deal, seeking a better offer or supporting Walgreens' turnaround plan under CEO Tim Wentworth. Shareholders can hold WBA stock to receive a $3.00 Divested Asset Proceed Right, adding a 26% return on the current stock price. Investors may also consider other four other consumer staples or drug retail stocks. Read the full article on Seeking Alpha
Seeking Alpha • Feb 11

Walgreens Boots Alliance: Larger Structural Problems Remain

Summary Walgreens-Boots Alliance faces severe structural issues, including margin compression, falling earnings, and weak balance sheet despite recent dividend cuts. The company is struggling with increased competition, labor shortages, and online retail pressures, leading to store closures and failed healthcare expansion. Significant uncertainties surround pending litigation and regulatory actions, with potential financial risks from opioid-related lawsuits and PBM practices. WBA remains overvalued compared to industry averages, lacking a viable plan to address core issues, making it a strong sell recommendation. Read the full article on Seeking Alpha
Seeking Alpha • Feb 03

Walgreens: Don't Expect The Dividend To Come Back Anytime Soon

Summary Walgreens Boots Alliance's dividend cut was necessary, in my view, given the challenged free cash flow, debt maturities, and mounting legal liabilities. WBA will likely generate only about $100-200 million of attributable cash in FY2026. The Footprint Optimization Plan aims to cut costs but also risks becoming a financial burden, with $2.2 billion in projected charges. Legal liabilities, particularly opioid litigation, threaten WBA's financial stability. Read the full article on Seeking Alpha
Seeking Alpha • Jan 08

Walgreens Could Have Reached Its Bottom, But Caution Is Still Advised

Summary Walgreens Boots Alliance has seen a significant decline in stock price, with my position down 75%, leading me to reaffirm my "Hold" rating. WBA's dividend yield is 10.5%, but sustainability is questionable due to negative free cash flow and significant debt levels. Walgreens' recent financial results show increasing sales but worsening operating losses and net losses, with future growth expectations being modest. Despite the low stock price suggesting undervaluation, Walgreens' profitability struggles and potential dividend cuts make it a risky investment. Read the full article on Seeking Alpha
Seeking Alpha • Dec 20

Walgreens' Rally Sputters Amid Takeover Chatter (Rating Downgrade)

Summary I am downgrading Walgreens Boots Alliance from a buy to a hold due to balanced risks and less compelling valuation. Despite a 10% gain since my September buy call, new fundamental developments and tepid M&A trends warrant a cautious stance. WBA's Q4 results beat expectations, but a soft FY 2025 guide, store closures, and ongoing sales pressures pose significant risks. Technically, WBA faces resistance at $11, with a trading range likely between $8-$11, making the stock less attractive. Read the full article on Seeking Alpha
Seeking Alpha • Dec 11

How Investors Should Assess The Potential Walgreens Buyout

Summary Walgreens surged 18% amid buyout rumors with Sycamore Partners, but the rally may be short-lived as markets cast doubt on the deal's feasibility. History: Walgreens' market cap plummeted from $100 billion in 2015 to $8.44 billion, with recent struggles including a write-down on VillageMD. Sycamore Partners may need partners for the acquisition, reducing deal likelihood; Walgreens could pursue internal plans to improve operations. Despite poor profitability and growth, Walgreens offers an attractive valuation and high yield, maintaining a 'hold' rating from Seeking Alpha Quant. Read the full article on Seeking Alpha
Seeking Alpha • Nov 18

Walgreens: 11.9% Dividend Yield Still On Unsteady Legs

Summary Walgreens faces ongoing financial challenges, including a potential future dividend cut, despite recent progress in cost-cutting and debt reduction. The company's 11.9% dividend yield is not covered by free cash flow, with legal fees and operational costs impacting cash flow sustainability. Management's turnaround efforts, including store closures and asset monetization, show promise but will take years to fully materialize. Investors should be cautious of the attractive yield, as the high likelihood of additional dividend cuts makes Walgreens a risky investment. Read the full article on Seeking Alpha
Seeking Alpha • Oct 29

Walgreens Q4: 2 Signs Of A Dividend Trap

Summary Walgreens Boots Alliance’s forward yield hovers around 10.8%, the highest among the S&P 500 index. Such yield raises concerns about a potential dividend trap due to bleak growth prospects and financial struggles, as reported in its recent Q4 earnings. Its Q4 earnings reveal significant challenges, including store closures and a bleak EPS growth outlook. Despite cost-cutting and divestiture efforts, WBA's heavy debt burden and declining cash flow may threaten dividend safety in the near future. Read the full article on Seeking Alpha
Seeking Alpha • Oct 23

Walgreens: Undervalued Pharma Giant Poised For A Turnaround Amid Cost-Cutting And Activist Investor Potential

Summary Walgreens Boots Alliance is significantly undervalued, trading at low P/E multiples and a 44% discount to its book value, with strong upside potential. New CEO Tim Wentworth's cost-cutting strategy and potential sale of VillageMD are expected to boost cash flow and equity value. Conservative valuation models (DCF, trading comps, exit multiple, GGM) indicate WBA is worth at least $28 per share, making it a strong buy. Risks include new management execution and competition from Walmart's pharmacy arm, but WBA's market share and cost-cutting plans provide a margin of safety. Read the full article on Seeking Alpha
Seeking Alpha • Oct 15

Walgreens: A Turnaround Stock To Avoid

Summary Walgreens plans to close 1,200 stores, impacting 13.79% of its total locations, to restructure and improve financial health. Despite beating Wall Street estimates, Walgreens' adjusted operating income fell 38%, and adjusted EPS dropped to $0.39 from $0.67 a year ago. The company's financials have been weak, with negative free cash flow and inconsistent performance, making it a risky investment. Walgreens needs to downsize stores significantly, focusing more on pharmacy operations, to survive long-term and improve profitability. Read the full article on Seeking Alpha
Seeking Alpha • Sep 29

Walgreens Stock: Cheap At 3x FWD P/E, But Still Not Worth Buying

Summary Walgreens is at risk of another dividend cut, as its free cash flow doesn't cover the current dividend payment, nor is it expected to in the next year. Walgreens faces intense competition, as other companies can offer the same products at a cheaper price. The company's low cash position relative to its debt is another reason why the dividend is at risk. The low P/E ratio is justified, given the company's current issues and the fact that EPS estimates may get revised lower, as they have in the recent past. Further, its price/FCF ratio is not nearly as attractive. Read the full article on Seeking Alpha
Seeking Alpha • Sep 06

Walgreens: Short Interest Surge Indicates It's Time To Cut Your Losses

Summary This article focuses on two new headwinds that recently developed for Walgreens Boots Alliance. The first one is a surge in its short interest to the 10%+ level, which could have negative feedback on its financials. The second one is the increased rollouts of direct-to-consumer pharmaceutical channels, which could further squeeze WBA’s margin space. The stock's valuation is extremely low in P/E (of ~3x), but its heavy debt makes it less attractive in EV terms. Read the full article on Seeking Alpha
Seeking Alpha • Aug 23

Is Walgreens Ready To Rebound?

Summary Walgreens issued $750 million in senior unsecured notes at 8.125%, refinancing 3.800% notes due in 2024, leading to a $32.4 million increase in annual interest costs. Walgreens sold its remaining Cencora shares for $1.1 billion, with a potential $55 million annual interest expense savings, reducing its ownership in Cencora from 12% to 10%. The $750 million raised will primarily reduce Walgreens' existing debt, signaling confidence in handling higher debt servicing costs. The funds will also be allocated for potential growth investments. Walgreens' partnership with Instacart to accept SNAP/EBT payments online at over 7,500 stores could potentially generate $200 million in annual sales, broadening its customer base. Walgreens reported a 37% YoY drop in adjusted EPS to $0.63 but highlighted $1 billion in targeted cost savings, potentially adding $400 million to operating income. Read the full article on Seeking Alpha
Seeking Alpha • Aug 13

Walgreens Boots Alliance: Likely A Value Trap, But Could Be A Speculative Long-Term Play

Summary Walgreens Boots Alliance, Inc. is a well-known pharmacy chain operating in the U.S., U.K., Germany, and internationally. Our previous investment thesis based on dividend discount model failed as WBA's stock declined by 70% despite attractive valuation results. The updated dividend discount model shows the stock is still undervalued, but risks, including dividend safety, debt, and market sentiment, make it a "hold". Read the full article on Seeking Alpha
Seeking Alpha • Aug 02

Walgreens: A Painful Turnaround Lesson

Summary As my worst investment in over 20 years, Walgreens Boots Alliance, Inc. stock served me a painful lesson about turnaround. Turnaround requires fundamentally sound business economics and plenty of financial resources. I misjudged Walgreens Boots Alliance's business economics badly. Recent developments also lead me to question if it has the financial resources to support a potential turnaround. Read the full article on Seeking Alpha
Seeking Alpha • Jul 09

Walgreens: Here's What Comes Next

Summary WBA stock drops 57% YTD, hitting 27-year lows, amid disappointing Q3 results and profit outlook cuts. Challenging environment with weak consumer spending and inflation pressures are impacting Walgreens' performance. Despite facing cash flow crisis and restructuring, WBA posts 2.6% sales growth driven by robust healthcare segment performance. Potential for rebound with aggressive cost-cutting and strategic shift to healthcare. By year-end, stock price targets range from $8.25 to $23.35, supported by volume price trends and RSI indicators. Read the full article on Seeking Alpha
Seeking Alpha • Jul 02

Walgreens: Yielding Over 8% Following The Earnings Drop

Summary Walgreens stock plummeted 56% in 2024, and is now trading below $12 a share. Quarterly dividend now yields 8%+, providing a potential opportunity for robust passive income. Challenges in the operating environment require new approach, potential store closures and divestitures in the future. Read the full article on Seeking Alpha
Seeking Alpha • Jun 24

Walgreens: Beware The Value Trap Ahead Of Earnings

Summary Walgreens Boots Alliance shares have cratered following the stock being removed from the Dow Jones Industrial Average. While Q2 2024 adjusted operating EPS beat expectations, its management team was not all that optimistic about the rest of the year. Shares are expected to be volatile after this week's earnings release. I highlight key price levels to monitor along with putting forward a valuation assessment. Read the full article on Seeking Alpha
Seeking Alpha • May 30

Walgreens: Another Dividend Cut Could Be Coming Soon (Rating Downgrade)

Summary Walgreens has faced headwinds and cut its dividend by nearly 50% earlier this year. The company's recent earnings showed some positive signs, but headwinds persist, which could lead to an additional dividend cut by the end of the year. The dividend coverage is a concern as operating cash flow and free cash flow were negative in the first half of the year. Their P/E of less than 5x is the lowest level seen since 1998, giving WBA an attractive dividend yield over 9%. Read the full article on Seeking Alpha
Seeking Alpha • May 22

5 Reasons Walgreens Fell By 6.4% To Nearly 25-Year Lows

Summary Walgreens Boots Alliance stock declined by 6.4% to a 25-year low of $16.68, a price not seen since 1998. Short interest, potential dividend cuts, and lingering ex-CEO worries are among reasons for the decline. Walgreens value grades compared to the sector discussed and compared to that of Humana, Cigna, CVS Health, and more. Read the full article on Seeking Alpha

CEO報酬分析

Walgreens Boots Alliance の収益と比較して、Tim Wentworth の報酬はどのように変化したか？
日付総報酬給与会社業績
May 31 2025n/an/a

-US$6b

Feb 28 2025n/an/a

-US$6b

Nov 30 2024n/an/a

-US$9b

Aug 31 2024US$13mUS$1m

-US$9b

報酬と市場: Timの 総報酬 ($USD 13.50M ) は、 US市場 ($USD 14.67M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Timの報酬と会社の業績を比較するにはデータが不十分です。

CEO

Tim Wentworth (65 yo)

1.8yrs
在職期間
US$13,497,004
報酬

Mr. Timothy C. Wentworth, also known as Tim, served as Director of Ushur, Inc. since February 2022. He served as the Chief Executive Officer of Evernorth at Evernorth Health, Inc. (formerly known as Expres...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Stefano Pessina
Executive Chairman of the Board13.3yrsUS$7.87m16.82%
$ 1.7b
Timothy Wentworth
CEO & Director1.8yrsUS$13.50m0.015%
$ 1.6m
Manmohan Mahajan
Executive VP & Global CFO2.1yrsUS$5.54m0.0071%
$ 733.6k
Ornella Barra
Chief Operating Officer of Internationalno dataUS$6.82m0.25%
$ 25.8m
Mary Langowski
Executive VP & President of Walgreens Healthno dataUS$6.65m0.0077%
$ 792.4k
Todd Heckman
Senior VP2.1yrsデータなし0.0027%
$ 273.4k
Matthew D'Ambrosio
Senior VP and Global Chief Compliance & Ethics Officerno dataデータなしデータなし
Lanesha Minnix
Executive VP & Global Chief Legal Officer1.3yrsデータなし0.0050%
$ 511.7k
Elizabeth Burger
Executive VP & Chief Human Resources Officer1.4yrsデータなし0.0058%
$ 594.3k
Liyue Wu
Head of M&A - Asiano dataデータなしデータなし
Tracey Brown
Executive VP3.8yrsデータなし0.0091%
$ 935.8k
Rick Gates
Senior VP & Chief Pharmacy Officer of Walgreen Co.2.4yrsデータなし0.0045%
$ 465.3k
2.1yrs
平均在職期間
54yo
平均年齢

経験豊富な経営陣: WBAの経営陣は 経験豊富 であると考えられます ( 2.1年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Stefano Pessina
Executive Chairman of the Board13.3yrsUS$7.87m16.82%
$ 1.7b
Timothy Wentworth
CEO & Director1.8yrsUS$13.50m0.015%
$ 1.6m
Ginger Graham
Lead Independent Director15.3yrsUS$3.50m0.00025%
$ 25.8k
Valerie Jarrett
Independent Director4.8yrsUS$300.00k0.00051%
$ 52.6k
Nancy Schlichting
Independent Director18.8yrsUS$469.99k0.0044%
$ 452.9k
John Lederer
Independent Director10.3yrsUS$320.00k0.0058%
$ 596.4k
Bryan Hanson
Independent Director2.8yrsUS$299.99k0.0055%
$ 568.5k
Janice Babiak
Independent Director13.3yrsUS$432.50k0.00014%
$ 14.4k
William Shrank
Independent Directorless than a yearデータなし0.00041%
$ 42.3k
Inderpal Bhandari
Independent Director2.9yrsUS$300.00k0.00035%
$ 36.1k
Thomas Polen
Independent Director2.1yrsUS$149.99k0.0033%
$ 337.4k
Robert Huffines
Independent Director1.6yrsUS$59.89kデータなし
3.9yrs
平均在職期間
66yo
平均年齢

経験豊富なボード: WBAの 取締役会 は 経験豊富 であると考えられます ( 3.9年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2025/08/27 23:06
終値2025/08/27 00:00
収益2025/05/31
年間収益2024/08/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Walgreens Boots Alliance, Inc. 11 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。23

アナリスト機関
Christopher GrajaArgus Research Company
Eric ColdwellBaird
Charley JonesBarrington Research Associates, Inc.